dm+d
73572009
Articles
Tool to calculate estimated dose equivalences of oral morphine to other oral opioids
14 September 2021Use our tool to obtain approximate dose equivalences of oral morphine to other oral opioids and help you calculate an estimated equivalent dose
Switching between oral morphine and other oral opioids in adult palliative cancer care patients
14 September 2021Switching between morphine and alternative opioids requires care and thoughtful application of a stepped process
How should medicines be dosed in children who are obese?
28 May 2021Review on how to calculate medicine doses in children who are obese which includes a table on commonly prescribed medicines.
What is the risk of interaction between opioids and monoamine oxidase inhibitors (MAOIs)?
10 November 2020**THIS ARTICLE IS CURRENTLY UNDER REVIEW**
Safety in Lactation: Opioid analgesics
21 October 2020The evidence relating to the safe use of opioid analgesics in breastfeeding mothers is very variable between individual drugs. This group of drugs presents a…
Medicine Compliance Aid Stability
ZomorphArchimedes Pharma UK Ltd
Archimedes Pharma UK Ltd
Zomorph
Capsules m/r - various strengths
A2 · Amber 2No stability data is available, the manufacturer does not, or cannot recommend use in CAs but there are no theoretical concerns with the product.
Protect from moisture
Protect from heat
Protect from moisture and heat.
11 May 2015
SevredolNapp Pharmaceuticals Ltd
Napp Pharmaceuticals Ltd
Sevredol
Tablets f/c - various strengths
A3 · Amber 3No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Airtight container
Protect from light
Airtight container and protect from light.
11 May 2015
Filnarine SRTeva Pharmaceuticals Ltd
Teva Pharmaceuticals Ltd
Filnarine SR
Tablets f/c, m/r various strengths
A3 · Amber 3No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
No special precautions for storage
No special precautions for storage.
11 May 2015
Morphgesic SRAmdipharm Mercury Co Ltd
Amdipharm Mercury Co Ltd
Morphgesic SR
Tablets f/c, m/r various strengths
A2 · Amber 2No stability data is available, the manufacturer does not, or cannot recommend use in CAs but there are no theoretical concerns with the product.
Airtight container
Protect from light
Airtight container and protect from light.
11 May 2015
MST ContinusNapp Pharmaceuticals Ltd
Napp Pharmaceuticals Ltd
MST Continus
Tablets f/c, m/r various strengths
A3 · Amber 3No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Airtight container
Protect from light
Airtight container and protect from light
11 May 2015
MXLNapp Pharmaceuticals Ltd
Napp Pharmaceuticals Ltd
MXL
Capsules m/r - various strengths
A2 · Amber 2No stability data is available, the manufacturer does not, or cannot recommend use in CAs but there are no theoretical concerns with the product.
No special precautions for storage
No special precautions for storage
11 May 2015
Lactation Safety Information
Except for low dose, immediate release oral formulations
Except for low dose, immediate release oral formulations
Other appropriate analgesic
Significant published evidence of use in breastfeeding
Small amounts in breast milk
Used in full-term neonates from birth
Infant monitoring advised, especially in young infants (see summary)
23 September 2020
Low dose, immediate release oral formulations
Low dose, immediate release oral formulations
Significant published evidence of use in breastfeeding
Small amounts in breast milk
Applies to short term, low dose (up to 10mg 4-hourly) oral solutions (e.g. Oramorph) and tablets
Although adverse effects in infant are not likely infant monitoring advised in young infants (see summary)
23 September 2020